Cardiorenal risk as a new frontier of nephrology: Research needs and areas for intervention

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 11, 2002, Pages 50-54

  Zoccali, Carmine ^a  

^a CNR   (Italy)

Author keywords

Cardiovascular; Chronic renal failure; Hypertension; Renal disease progression; Risk

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CALCIUM PHOSPHATE; CREATININE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ALDOSTERONE BLOOD LEVEL; ANEMIA; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; MALE; MEDICAL RESEARCH; MORBIDITY; MORTALITY; NEPHROLOGY; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

EID: 0036415123     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_11.50     Document Type: Article

References (24)

1. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906
2. Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: time to end the 'only-50%' myth. Arch Intern Med 2001; 161: 2657-2660
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc 1986; 256: 2823-2828
4. Jones CA, McQuillan GM, Kusek JW et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32: 992-999
5. Culleton BF, Larson MG, Evans JC et al. Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study. Arch Internal Med 1999; 159: 1785-1790
6. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke 1997; 28: 557-563
7. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001; 161: 886-891
8. Excerpts From United States Renal Data System 1999 Annual Data Report: II. Incidence and prevalence of ESRD. Am J Kidney Dis 1999; 34 [2 Suppl 1]: S40-S50
9. Johnson R, Herrera-Acosta J, Schreiner GF, Rodriguez Iturbe B. Mechanisms of disease: subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346: 913-923
10. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141
11. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991; [Suppl]: 31: S29-S34
12. Brocco E, Fioretto P, Mauer M et al. Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int 1997; [Suppl]: 63: S40-S44
13. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
14. Hoogeveen EK, Kostense PJ, Jager A et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998; 54: 203-209
15. Chauveau P, Chadefaux B, Conde M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; [Suppl]: 41: S72-S77
16. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049-1057
17. Kielstein JT, Boger RH, Bode-Boger SM et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-176
18. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117
19. Valkonen VP, Paiva H, Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128
20. Jungers P, Zingraff J, Albouze G et al. Late referral to maintenance dialysis: detrimental consequences. Nephrol Dial Transplant 1993; 8: 1089-1093
21. Kissmeyer L, Kong C, Cohen J, Unwin RJ, Woolfson RG, Neild GH. Community nephrology: audit of screening for renal insufficiency in a high risk population. Nephrol Dial Transplant 1999; 14: 2150-2155
22. Baggio B, Budakovic A, Perissinotto E, Maggi S, Enzi G, Grigoletto F. Renal function and cardiovascular risk factors in an Italian elderly population: results of the ILSA study. J Nephrol 2001; 13: 461 (abstract)
23. Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998; 13: 3091-3095
24. Wanner C, Krane V, Ruf G, März W, Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on haemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int 1999; 56 [Suppl 71]: S222-S226